Skip to main content
Equibles
CRBU logo

CRBU · Caribou Biosciences, Inc. · Documents

Track CRBU — free

Use CRBU with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CRBU.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.38 -0.01 (-2.69%) At close · Nov 12
Russell 2000 member Rebalance outlook locked
Market Cap
$41.08M
Shares
108.04M
Volume · Nov 12 1.54M Avg daily vol (3M) 2.72M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $11.16M up 11.7% 10-K filed Mar 5, 2026 Quarterly report FY2026 Q3 Revenue $1.61M down 26.9% 10-Q filed Nov 5, 2026 Latest results Strategic Review Includes Discontinuing Two CAR-T Programs 8-K filed Nov 5, 2026
2026
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Strategic alternatives sought as clinical programs wind down

Caribou Biosciences is exploring strategic alternatives, including possible dissolution, while discontinuing vispa-cel and CB-011 development, substantially reducing its workforce and cutting costs. It held $94.8 million in cash, cash equivalents and marketable securities as of September 30, 2026.

Revenue $1.61M ▼ 26.9% Net loss $26.61M Diluted EPS -$0.25
Read from the MD&A section
3 source passages
Included in our 2026 Restructuring is the planned discontinuation of our clinical trials and further development activities for our two clinical-stage allogeneic chimeric antigen receptor (“CAR”)-T (“CAR-T”) cell therapies (vispa-cel and CB-011), a substantial reduction of our workforce, and other cost reduction measures. Our Board established a transaction committee to explore, evaluate, and make recommendations to our Board regarding strategic alternatives and engaged Wedbush Securities Inc. as the exclusive financial advisor to assist in the strategic alternatives process. As of September 30, 2026, we had cash, cash equivalents, and marketable securities of $94.8 million. Open the document at this passage
Nov 5
Current report 8-K
Strategic Review Includes Discontinuing Two CAR-T Programs

Caribou Biosciences is exploring strategic alternatives and restructuring that will discontinue vispa-cel and CB-011 development. It reported a $26.6 million net loss and $94.8 million in cash, cash equivalents and marketable securities as of September 30, 2026.

Financial results
3 source passages
On October 6, 2026, Caribou Biosciences announced that it will explore strategic alternatives to maximize stockholder value, including the planned discontinuation of clinical trials and further development activities for two allogeneic CAR-T cell therapy programs, vispacabtagene regedleucel (vispa-cel) and CB-011. Caribou reported a GAAP net loss of $26.6 million, or $0.25 per share, basic and diluted, for the three months ended September 30, 2026, compared to $27.5 million, or $0.30 per share, basic and diluted. Caribou had $94.8 million in cash, cash equivalents, and marketable securities as of September 30, 2026, compared to $142.8 million as of December 31, 2025. Open the document at this passage
Aug 13
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.5M ▼ 43.8% Net loss $24.28M Diluted EPS -$0.24
May 7
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $2.4M ▲ 1.9% Net loss $25.09M Diluted EPS -$0.26
Mar 5
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $11.16M ▲ 11.7% Net loss $148.13M Diluted EPS -$1.59
2025
Mar 10
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $9.99M ▼ 71.0% Net loss $149.11M Diluted EPS -$1.65
2024
Showing 1–50 of 127 documents
Key facts CIK 1619856 CUSIP 142038108 13F (30d) 94 filings 81 filers Visit website Investor relations